Sequana Medical NV (STU:2SE) ROCE % : -254.81% (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Sequana Medical NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sequana Medical NV's annualized ROCE % for the quarter that ended in Jun. 2023 was -254.81%.

Sequana Medical NV ROCE % Historical Data

The historical data trend for Sequana Medical NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequana Medical NV ROCE % Chart

Sequana Medical NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-291.06

-287.37

-320.57

Sequana Medical NV Semi-Annual Data
	Dec15	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial									-167.76	-172.52	-178.53	-198.66	-254.81

Sequana Medical NV ROCE % Calculation

Sequana Medical NV's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-29.496	/	( ( (14.705 - 7.18)	+	(26.025 - 15.148) )	/ 2 )
	=	-29.496	/	( (7.525	+	10.877)	/ 2 )
	=	-29.496	/	9.201
	=	-320.57 %

Sequana Medical NV's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-28.2	/	( ( (26.025 - 15.148)	+	(25.127 - 13.87) )	/ 2 )
	=	-28.2	/	( ( 10.877	+	11.257 )	/ 2 )
	=	-28.2	/	11.067
	=	-254.81 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Sequana Medical NV (STU:2SE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sequana Medical NV ROCE % Related Terms

Thank you for viewing the detailed overview of Sequana Medical NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequana Medical NV (STU:2SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sequana Medical NV (STU:2SE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2SE:Germany SEQUA:Belgium

Address

Kortrijksesteenweg 1112 ,bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051

Website

https://www.sequanamedical.com

Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies and over 750 implants. The company's geographical segments include Switzerland, Germany, the United Kingdom, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

Sequana Medical NV (STU:2SE) Headlines

No Headlines